NYSE:OMI Owens & Minor Q2 2024 Earnings Report $6.91 -0.06 (-0.86%) Closing price 04/25/2025 03:59 PM EasternExtended Trading$6.86 -0.04 (-0.65%) As of 07:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Owens & Minor EPS ResultsActual EPS$0.36Consensus EPS $0.33Beat/MissBeat by +$0.03One Year Ago EPS$0.18Owens & Minor Revenue ResultsActual Revenue$2.67 billionExpected Revenue$2.65 billionBeat/MissBeat by +$24.60 millionYoY Revenue Growth+4.20%Owens & Minor Announcement DetailsQuarterQ2 2024Date8/2/2024TimeBefore Market OpensConference Call DateFriday, August 2, 2024Conference Call Time8:30AM ETUpcoming EarningsOwens & Minor's Q1 2025 earnings is scheduled for Friday, May 2, 2025, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q1 2025 Earnings ReportConference Call ResourcesConference Call AudioConference Call TranscriptSlide DeckPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Owens & Minor Q2 2024 Earnings Call TranscriptProvided by QuartrAugust 2, 2024 ShareLink copied to clipboard.There are 10 speakers on the call. Operator00:00:00Good day and thank you for standing by. Welcome to the Owens and Minor Second Quarter 2024 Earnings Conference Call. Please be advised that today's conference call is being recorded. I would now like to hand the conference over to your first speaker today, Jackie Marcus, Investor Relations. Jackie, you may begin. Speaker 100:00:22Thank you, operator. Hello, everyone, and welcome to the Owens and Minor Second Quarter 2024 Earnings Call. Our comments on the call will be focused on the financial results for the Q2 of 2024 as well as our outlook for 2024, both of which are included in today's press release. The press release, along with the supplemental slides, are posted on the Investor Relations section of our website. Please note that during this call, we will make forward looking statements. Speaker 100:00:52The matters addressed in these statements are subject to risks and uncertainties, which could cause actual results to differ materially from those projected or implied here today. Please refer to our SEC filings for a full description of these risks and uncertainties, including the Risk Factors section of our annual report on Form 10 ks and Quarterly Reports on Form 10 Q. In our discussion today, we will reference certain non GAAP financial measures and information about these measures and reconciliations to the most comparable GAAP financial measures are included in our press release. Today, I am joined by Ed Paseka, Owens and Minor's President and Chief Executive Officer and John Leon, the Interim Chief Financial Officer and Senior Vice President of Finance and Corporate Treasurer. I will now turn the call over to Ed. Speaker 200:01:45Thank you, Jackie. Good morning, everyone, and Speaker 300:01:47thank you for joining us on Speaker 200:01:48the call today. It's been an exciting past few weeks here at Owens and Minor. Last Tuesday, we shared with all of you our definitive agreement to acquire Rotech Healthcare Holdings Incorporated. The addition of Rotech aligns with our strategy to strengthen and expand our existing patient direct business as one of the premier suppliers to support home based care. Combining our organizations allows us to improve our capabilities, broaden our reach and ultimately improve our service levels to patients, providers and payers. Speaker 200:02:21And furthermore, it accelerates our pace to achieve our long term patient direct revenue target of $5,000,000,000 by 2028, demonstrating our commitment to sustainable growth and driving long term shareholder value. Turning to our Q2 performance, it was business as usual for Owens and Minor as we hit our internal expectations with another strong quarter and made progress against our long term strategic goals we outlined during our Investor Day in December of 2023. The underlying strength of our business is evident with top line growth in both of our business segments and improved profitability. We are excited about the second half of twenty twenty four as we expect to outperform the first half of this year, a continuation of historical trends with strong back half performances. While John Leon, our Interim Chief Financial Officer will do a more thorough review of our financials, I would like to briefly highlight a few of our operational and financial achievements from the Q2. Speaker 200:03:24Our Products and Healthcare Service segment generated $2,000,000,000 in revenue, reflecting a 4% improvement over this time last year. Our Medical Distribution division's strong Q2 was the result of exceptional same store sales growth, enhancement in our supplier funding programs and the onboarding of new business wins. Our Global Products division also experienced some growth at the top line and further improvements in profitability. At our Investor Day, we outlined our plan to optimize the P and HS segment through 1, leveraging the scale of the channel profitability 2, growing our Owens and Minor branded product portfolio and 3, expanding into adjacent channels and markets. In our first two quarters of 2024, we are already making progress in these areas with a particular focus on driving greater efficiencies that in the Q2 reduced our manufacturing, transportation and distribution costs. Speaker 200:04:25These efforts combined with inflation mitigating tactics gave us the financial flexibility to reinvest in our business while also doing exactly what we said we would do, increasing the overall profitability of this segment. Our Patient Direct segment posted $660,000,000 in revenue in the 2nd quarter, a 4% year over year improvement, driven by strong growth in diabetes and sleep supplies. Our growth is even more impressive given the particularly strong second quarter we had this time last year. During the quarter, we continue to focus on our key initiatives along with our alignment on the commercial organization within the Apria division to improve growth in respiratory, oxygen and the sleep journey. By the end of the quarter, we began to see that alignment deliver improved growth. Speaker 200:05:16As a reminder, we typically see stronger performance from this segment in the second half of the year and we expect a similar outcome in 2024. From a longer term macro perspective, our Patient Direct segment has considerable tailwinds supporting our organic growth efforts. From a demographic perspective, there are an estimated 133,000,000 Americans who suffer from at least one chronic condition, with 40% of American adults suffering from multiple chronic conditions and many more still not yet diagnosed, particularly in diabetes and sleep apnea. These demographic trends make us excited about our Patient Direct segment despite the groundswell of support for weight loss medications. Moreover, we are not currently seeing an impact from the use of GLP-1s on our served patient population. Speaker 200:06:08The diabetic patients we serve are primarily type 1 or insulin dependent, which requires continuous glucose monitoring regardless of GLP-one use. With respect to sleep apnea patients, while GLP-1s may help some patients, there are still 80% of the population with sleep apnea that are not yet diagnosed. As I noted earlier, we announced our intent to acquire ROTEC, which will be an expansion of our Patient Direct segment. Rotech brings a wealth of expertise in respiratory and home medical equipment, aligning perfectly to deliver exceptional care, innovative solutions and top notch service levels for patients, providers and payers. Being just a few months into our long term strategic plan, we are progressing as expected in both segments. Speaker 200:06:56Our team has done a tremendous job in just the 1st two quarters since launching our Vision 2028 plan at Investor Day. From driving efficiencies, improving customer service, to building strong organic growth channels and the plan to add Rotech to our Patient Direct segments, all of which proves we're on the right path and only just getting started. We remain dedicated to achieving the objectives set forth during our Investor Day in December 2023 and our performance thus far reflects that commitment. I would now like to turn the call over to our Interim Chief Financial Officer, John Leon to discuss our Q2 financial performance in more detail. John? Speaker 400:07:39Thanks, Ned, and good morning, everyone. I will be providing an overview of our financial results and some key factors that drove our performance in the 2nd quarter, as well as our outlook for the remainder of the year. Our revenue for the quarter was $2,700,000,000 up 4% compared to the prior year with solid growth in both segments. Products and Healthcare Services grew 4% overall as compared to the prior year with 5% year over year growth in our medical distribution division as same store sales and net new customer wins drove the top line change. Patient Direct revenue of $660,000,000 was up 4% compared to the Q2 of last year. Speaker 400:08:21Major therapy categories like diabetes, sleep supplies and wound again had strong performance, although certain respiratory therapies such as NIV and oxygen were below expectations. Within Patient Direct, patient eligibility verification continued to regain momentum. However, a meaningful yet decreasing backlog of customers extended into the Q2. We should be clear of these onboarding timing issues as we move through the second half of the year. Gross profit in the second quarter was $544,000,000 or 20.4 percent of net revenue, reflecting margin expansion of 11 basis points as compared to the Q2 of last year. Speaker 400:09:02This improvement is largely the benefit of investments in efficiency and productivity over the last several months. Our distribution, selling and administrative expenses for the quarter were 469,000,000 dollars up from $455,000,000 in the Q2 of 2023. The increase is primarily due to sales growth as DS and A was just below 18% of revenue for both this year and last year. GAAP operating income for the quarter was 20,300,000 dollars up 87% year over year and adjusted operating income was $76,300,000 Adjusted operating income was up 23% year over year. Interest expense for the Q2 was $36,000,000 down 12% compared to $41,000,000 in the Q2 of 2023. Speaker 400:09:50This is largely due to the nearly one full term reduction in leverage in the last 12 months, partially offset by the impact of higher interest rates versus last year. In the Q2, we recorded a one time tax charge of $17,000,000 or $0.22 per share related to a recent decision associated with notices of proposed adjustments that we received back in 2020 2021. This was just communicated to us in late June of 2024. Due to the nature of this charge, this item is included in our GAAP to non GAAP reconciliations. The matter at hand, as we've discussed in previously filed SEC documents, is related to past transfer pricing methodology, which is no longer employed. Speaker 400:10:33There is an expected related cash payment to be made in the second half of the year in a range of $30,000,000 to $35,000,000 We believe the matter will be concluded without further impact to our financial results. Our GAAP effective tax rate reflects this charge and was negative 89.9 percent for the quarter. The adjusted effective tax rate was 28.9%. Our GAAP net loss for the quarter was $31,900,000 or a loss of $0.42 per share compared to the Q2 of last year when the net loss was 28,200,000 dollars or $0.37 per share. Adjusted net income for the quarter doubled to $28,200,000 or $0.36 per share from $14,200,000 or $0.18 per share during the Q2 of 2023. Speaker 400:11:18Adjusted EBITDA was $127,000,000 up 12% versus $113,000,000 reported in the Q2 of last year. Also we generated $116,000,000 of operating cash flow this quarter, a strong improvement versus Q1 of 2024. This will allow us to reduce net debt by $70,000,000 We anticipate a good cash flow generation year that will include typical lumpiness quarter to quarter and we remain intensely focused on cash flow generation. With respect to our current outstanding debt, we have $171,000,000 of a series of notes which is due in December of this year. Earlier this week, we gave notice to redeem those notes at par in September and we'll do so with cash on hand. Speaker 400:12:01We remain committed to delivering our 2024 guidance. We expect revenue to be in the range of $10,500,000,000 to $10,900,000,000 adjusted EBITDA to be in the range of $550,000,000 to $590,000,000 and adjusted EPS with a midpoint of $1.55 per share and overall range of $1.40 to 1 0.70 Now as in prior years, we expect to see modest sequential growth between the 2nd and the 3rd quarters and greater sequential growth from the 3rd to the 4th quarter. And again, I want to remind you that this guidance excludes any impact of the Rotech acquisition. With that, I'll turn the call over to the operator for the Q and A session. Operator? Operator00:12:42Thank you. We will now begin the question and answer session. Your first question comes from the line of Michael Cherny with Leerink Partners. Please go ahead. Speaker 500:13:03Good morning and thanks for taking the question. Operator00:13:11My apologies. Can you press star 1 again please? Speaker 200:13:16Sorry, Michael, we lost you. Speaker 400:13:23Operator, why don't we move on to the next question and Mike will get back in line. Yes. Operator00:13:27Michael, your line is now open. Speaker 500:13:30Hi. Can you hear me this time? Speaker 200:13:32We can, Michael. Speaker 500:13:34Okay. That was a first. We'll see if that happens again. Speaker 400:13:37Sorry about that. I don't know what happened. Speaker 500:13:41Yes. Called a Friday. That's right. Speaker 400:13:44I want to talk about some Speaker 500:13:45of the operational plans that you've had put in place, in particular the progress you made on the products and healthcare services side. As you think about the moving pieces on margins, you were kind of flat sequentially. Where are the biggest opportunities to expand in the back half of the year? Is it volume? Is it that unlocking of the backlog of customers? Speaker 500:14:06And how does the dynamics around the tariffs that are expected to go into place impact and not impact you relative to the sourcing side? Speaker 200:14:16Let me take those probably somewhat in reverse orders. From on the tariff aspect, it's going to have a minimal impact on us since significant portion of our products are manufactured in our own facilities, whether that's in the U. S. Or whether that's in Mexico, Honduras, so in the Americas. Our glove footprint is not in China. Speaker 200:14:35We have, as we've talked in the past about more than half of our gloves we're making in our own factories and those factories are in Southeast Asia, not in China. So it's going to have minimal impact really on our proprietary, our private label products. If I think about the levers we have in the back half of the year within our product and healthcare services, it's the continued execution on sourcing. As we've seen prices come down in overall, let's just take it main category of PPE, we've done a really good job continuing to source raw materials at lower rates to make sure that as those prices come down, our costs are coming down correspondingly with them. The other aspect of it is really in operational effectiveness in our P and HS segment. Speaker 200:15:23Continue to look at our footprint, continue to look at the right level of new advanced automation and technology in the warehouses to drive operating efficiencies. So we saw some of the improvement in this quarter in DS and A or distribution selling and administrative expenses. There's where the opportunities continue to lie. Longer term, if you go back to our strategy, really the longer term impact is the expansion of our private label or proprietary product portfolio that takes time as we build the product portfolio out and then continue to work with our customers to show the value of it. And then even further along the line is adjacency. Speaker 200:16:02So hopefully that helps talk about really how we're thinking about the impact of the tariffs, how we're thinking about using our continuous improvement and operating model to continue to drive operating efficiencies out and then some of the longer term and midterm opportunities. Speaker 400:16:21Thanks, Ed. If I can just ask a Speaker 500:16:22second one on cash flow. Speaker 400:16:26I know that was Speaker 500:16:26a big focal point earlier in Speaker 400:16:28the year when you gave guidance, you talked about some of Speaker 500:16:30the customer onboarding. Can you talk about the dynamics behind the reversal this quarter and how that should factor in, in terms of your cash generation versus use, over the course of the year, especially as you think through normalizing the onboarding of some of those large customer wins you had? Speaker 400:16:46Yes, Mike, it's John. So obviously, as you mentioned, we talked before about the need to add inventory for those onboarding activity and that could also slow down AR a little bit when you bring on large customers like we did in distribution. What you saw in Q2 was a little more lift in inventory, but that was offset by payables and payables kind of offset that pretty nicely. Like Q1, we also had the quarter end on a Friday, which is actually beneficial to our payables. And we have been pretty successful in driving out payment terms where appropriate with parties. Speaker 400:17:18So that combination is going to continue to help us out in the back half of the year. But people might also get the seasonality in the back half of the year, particularly in Patient Direct, which will have very well, it's very attractive cash flow as the year goes on. And their contractual allowances should drop as the year goes on as well. So I think we'll see more efficiency. Consequently, we'll see more efficiency in working capital around payables, we see those in inventory. Speaker 400:17:44And if you look at the seasonal list now, keeping in mind that what you're looking at is a point in time at the last day of the quarter. So we're actually more efficient in Q2 than we saw. For example, average inventory was lower than it was at the very end of the quarter. So we were able to get that cash flow and reduce debt. But I think as the year goes on, that working capital efficiency and then the seasonality business will drive pretty attractive cash flow compared to the first half of the year. Speaker 500:18:11So will you have meaningful cash flow conversion over the course of the year? I know that was a point of contention earlier in the year. Speaker 400:18:17We will do. I would be very disappointed if we didn't do quite a bit better in the second half than we've done in the first half. Got it. Thanks so much. Operator00:18:28Your next question comes from the line of Kevin Caliendo with UBS. Please go ahead. Speaker 600:18:35Good morning, guys. Thanks for taking my question. Speaker 300:18:40First, can we talk a Speaker 600:18:41little bit, there's been a lot of interest around what's going on with shipping costs and how it impacts the channel. The tariffs are one thing, but the shipping costs have the ones that we can track anyways have risen dramatically. And I guess I'm trying to understand how it impacts you, how it impacts the industry. Does it help you that you're sure and does it make your products that are manufactured domestically more attractive? Just trying to understand the impact across channel. Speaker 200:19:13Yes. So it's primarily an impact on the PNHS segment, not necessarily in the Patient Direct segment. Yes, for those products that we're manufacturing nearshore, it has to create some level of an advantage for us. But again, I talked earlier that about half of our gloves were making our own factory in Southeast Asia and bringing them over. It's impacted us in a couple of different ways. Speaker 200:19:37As we started to see those rates start to rise, we have made some investment in incremental inventory coming over in advance of some of those larger increases that we're seeing in the marketplace. But ultimately, this is going to have a bigger impact on those that do primarily all of their sourcing or the vast majority of their sourcing from overseas. Look, it's a headwind that we know we have in the business. It's also part of how do we utilize our operating model to continue to try to offset that, whether it's advanced shipments prior to some of those increases, but also continue to look at different ways to more efficiently bring the product over. But it is going to create some level of a headwind in the business in the back half of the year. Speaker 600:20:23So what you're saying is you're trying to get product in sooner, maybe you're going to build up more inventory before it starts to affect as much as you possibly can and hope that customers will be willing to buy those sooner because they know the prices are likely to go higher. Does that in general? Speaker 200:20:43And it may not even necessarily them buy the product sooner. It's just to have a better landed cost on the product than Speaker 400:20:51not. Good. Speaker 600:20:54Maybe this is one for Jonathan. The patient direct ramp in the second half is there it's a little bit more than normal seasonality, it looks like to me. Can you just give us a little bit of comfort or rationale behind why that there will be this acceleration? I know there were investments, but if you can maybe go a little deeper on that, that would be great. Speaker 400:21:19Yes, Kevin. The biggest factor, as I indicated in my remarks, was that we're still dealing with the backlog in Patient Direct that frankly is a holdover from change that we probably underestimated because the extent of that impact in Q1 to Q2. We have a normal queue of people waiting for supplies all the time, but this is substantially larger than it would normally be. And those are primarily sleep patients. So it's a little more process associated with them. Speaker 400:21:47So if you factor that, we are catching up. There's a lot of manual effort going to that catch up, but we are catching up and we're clearing that backlog. So you take that combination then with the normal seasonality in the business, we're pretty confident in a much stronger second half. Speaker 200:22:03And I'll just add 2 other things as one is we clearly understood that when we added additional commercial resources, they would create some level of I'm going to call it disruption, but some level of impact in the beginning of the year here with the expectation that it takes about 12 months for them to provide a positive impact. So we'll see that as that progresses in the year. The other thing, if you look at Q2 year over year, last year Q2 growth rate was pretty strong. So those are some other factors that give us the comfort in the back half of the year and the growth. Speaker 400:22:35Great. Thank you, guys. Thanks, Kevin. Operator00:22:38Your next question comes from the line of John Stansl with JPMorgan. Please go ahead. Speaker 300:22:44Great. Thanks for taking the question. Just following up on the plan around Patient Direct. Is there just a way to frame, given you have some visibility into this backlog about how you think about the impact on patient direct top line growth? And then now that we're kind of a month into the Q3, is this something that you think now is this change is kind of coming in the rear view that will be more of a 3Q benefit? Speaker 300:23:08Or is this something that kind of could progress into 4Q? Speaker 400:23:13Yes, John. It's John William. It wouldn't help me think about it. So what happens, the eligibility verification process had become very manual very quickly. And we're doing a very good job of clearing that and getting better at that and bringing on new providers to help us with that process. Speaker 400:23:30A way to think about it, and I would call it back over at any point in time, there's a queue of 10,000 customers waiting for supplies and that we saw that into June growth was much as 50,000. So that is getting better now that we're getting to the 3rd quarter will continue to get better throughout the year. But that has certainly impacted the growth. And as I said earlier, a lot of it is predominantly sleep supplies and that's very attractive margin business that we're waiting to get online. Speaker 300:23:58Great. And then just kind of thinking about gross margins that have stepped down sequentially from the Q1. Now I normally think of this as kind of gross margin stepping up throughout the year. Is that kind of slight step down that you saw, is that more kind of attributable to the patient direct, I guess, mix shift? Or is there other factors you highlight about kind of what drove that? Speaker 300:24:22And then I would assume, giving reaffirmed guidance, we should just see a bit of a steeper ramp into the back half for gross margins. Is that kind of the right way to think about it? Speaker 400:24:30That is the right way to think about it. Yes, mix shift in patient direct can be meaningful, and we've thought that before that sleep and respiratory areas have higher margin, things like diabetes, which has been growing very nicely for us. Speaker 300:24:43Great. Thank you. Operator00:24:46Your next question comes from the line of Stephanie Davis with Barclays. Please go ahead. Speaker 700:24:52Hey guys, thank you for taking my questions. Now that you've had a little bit of time to just have the market digest the Rotech acquisition announcement, I was hoping you could tell us about some initial feedback from your payer and provider customers and how they're thinking about the deal? Speaker 200:25:08Yes. I'll just talk a little maybe I'll start it at a high level. I think it's been clear the feedback has been that this is clearly in line with the strategy you talked about, about continuing to invest inorganically, specifically in the Patient Direct space, continuing to provide a better solution. It's still early on. So to get the patient and the payer feedback, that's still in process. Speaker 200:25:34But overall, it's been extremely positive. I think overall from a standpoint, we believe that this is going to ultimately provide a much better experience for the patient, the ability to focus on a single company to support them as well as be able to get their products hopefully potentially more efficiently. And then the same with the payers being able to have continue to work with us. So it's early on. I think we'll continue to gather that information, but that's where we are on it right now. Speaker 700:26:07And a follow-up on Patient Direct, you did call out some weakness in the quarter on NIV and oxygen. Could you call out any trends or if that's more of a one off with the owned business just given the exposure at Rotex? Speaker 400:26:25No, I would tell you what we've seen from now a couple of quarters now, Stephanie, we've talked about when we're not doing what we should be doing, expect to do in terms of growing, NIV and oxygen. I would call that unique to us. I'm confident saying that's unique to us and we have plans in place and working on that to remedy that in the back half of the year. Speaker 700:26:45Okay. Maybe some learnings from the new deal. Thank you much. Speaker 400:26:48Exactly. Exactly. Operator00:26:51Your next question comes from the line of Daniel Groeslait with Citi. Please go ahead. Speaker 800:26:58Hi, thanks for taking the question. Let me go back to some comments you made around cash flow and that being meaningfully you expect that to be meaningfully better in the second half versus the first half. That would put you in kind of solidly positive free cash flow territory for this year versus your commentary last quarter where you thought you would be effectively flat or no free cash flow this year. So I'm just curious what changed in your thinking? Where are you outperforming your initial in the back half of this year? Speaker 800:27:39What's in the Speaker 200:27:40back half of this year? Speaker 400:27:43Well, yes, it does. First of all, Dave, it's John. Secondly, I would tell you the increased confidence in cash flow comes around our focus and the visibility into the working capital activities currently underway. We've talked about last couple of quarters about the inventory ramp and talked earlier about inventory being a little bit higher now for some shipping purposes getting ahead of that curve. But even throughout most of the second quarter, we saw inventory be pretty well moderating compared to Q1, We're in full a bit late in the quarter, but I think as we think about that and we get a little smarter about our AP and our AR and getting better terms from folks, I think we're pretty confident that cash will get better as the year goes on. Speaker 400:28:29We're seeing better collections on a regular basis that had a patient direct to the field. Speaker 800:28:35Got it. Okay. Okay. And there were some legal expenses this quarter, I think related to the Apria. Just curious what's driving that and if you expect to see increased legal expenses for the remainder Speaker 200:28:52of the year this quarter? Speaker 400:28:53No, nothing going forward. That was a one time settlement, an action that began before we bought Apria. So that has now been failed and behind us. So there'll be nothing else going forward associated with that. Okay, great. Speaker 400:29:06Thank you. Operator00:29:10Your next question comes from the line of Eric Coldwell with Baird. Please go ahead. Speaker 900:29:17Thank you very much. I apologize if I missed a couple of these. For some reason I've had a hard time with the connection here, just a little bit hard to understand some things. In 2Q, did you break out the difference between medical distribution growth and products growth that combined to got you to the 4%? Did you give the growth rate? Speaker 900:29:42No, Speaker 200:29:43we did not. Speaker 900:29:45Can you? Speaker 400:29:49Well, I think we said net distribution grew 5% and overall segment grew 4%. So, I think Okay. Speaker 900:29:55I didn't hear that. It's been a bad connection today. Yes. Okay. And then on the cash flow, I know you've given a number of reasons why it improves, but I still am not sure why the original guidance was flat and now it's so much different. Speaker 900:30:16What was it that you're just fundamentally managing the business differently or things you expected through Q1 up to the last call just they're turning out differently than you originally expected. It just seems like a very different conversation 90 days later than it was 90 days ago. Speaker 200:30:38I think that's fair, Eric. And I think it comes down to as one is focus As we continue to look forward, I think you've got better visibility now into forecasting of where we think it where the opportunities in the lever are. And then it's execution on some of the initiatives we have to drive working capital improvement. So that's those three major factors are where it is. It's the focus, it's improved forecasting and our ability to execute on some of those opportunities. Speaker 900:31:11Great. And I'll just going to go back to the medical distribution growth of the 5%. Would you be capable of breaking out how much of that growth was market versus new wins? Yes. Or was it same store versus new wins? Speaker 200:31:28Yes. I think it's if I think about the 2 of them, they're relatively consistent. I mean so what's hard to do is our same store sales, if we look at our same store sales, they're consistent with that 4% and then our wins are consistent to help move that up further. And then there's still some remnants of some other losses we've had in the past that are rolling out. So that's the way I would think about it is from that standpoint. Speaker 900:31:55Got it. Okay. Thank you very much. I appreciate it. Operator00:32:00That concludes our question and answer session. I will now turn the conference over to Ed Paseka for closing comments. Speaker 200:32:07So thanks everyone and excited and thankful that everyone joined the call today. If we think about the future at Owens and Minor, we're extremely excited of what's yet to come in here. We continue to execute on our long term strategy. We continue to focus on our operating model. We continue to get excited about the potential and future integration and approval with the Rotech, rolling that into our patient direct business, which will provide, we believe, significant better service for our patients, providers as well as the payers and really pleased with the progress we've made to this point in time in our product and healthcare services business. Speaker 200:32:44So with that, appreciate the time today and look forward to talking again next quarter. Thank you. Operator00:32:49This concludes today's conference call. Thank you for your participation and you may now disconnect.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallOwens & Minor Q2 202400:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsSlide DeckPress Release(8-K)Quarterly report(10-Q) Owens & Minor Earnings Headlines3 Reasons OMI is Risky and 1 Stock to Buy InsteadApril 25 at 8:47 AM | finance.yahoo.comOwens & Minor plans opening, sues WestRidge to void original leaseApril 25 at 3:47 AM | yahoo.comWho’s really running AmericaMost Americans have never heard his name… He was instrumental in Trump’s victory. He turned J.D. Vance from a Trump-hater into his vice president. He’s one of the driving forces behind the rise of cryptocurrencies, digital commerce, social media, Big Data, cloud computing, and artificial intelligence... In other words, he’s America’s puppet master. April 28, 2025 | Porter & Company (Ad)Owens & Minor, Inc. (NYSE:OMI) Given Average Recommendation of "Hold" by AnalystsApril 25 at 2:13 AM | americanbankingnews.comOwens & Minor (OMI) to Release Quarterly Earnings on FridayApril 25 at 1:05 AM | americanbankingnews.comOwens & Minor: Lots Of Moving PartsApril 24, 2025 | seekingalpha.comSee More Owens & Minor Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Owens & Minor? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Owens & Minor and other key companies, straight to your email. Email Address About Owens & MinorOwens & Minor (NYSE:OMI) is a healthcare solutions company, which engages in the product manufacturing and delivery, home health supply, and perioperative services to support care through the hospital and into the home. It operates through the Products and Healthcare Services, and Patient Direct segments. The Products and Healthcare Services segment includes medical distribution, the outsourced logistics and value-added services business, and global products, which manufacture and source medical surgical products through the production and kitting operations. The Patient Direct segment includes the home healthcare business, Byram and Apria. The company was founded by Otho O. Owens and G. Gilmer Minor in 1882 and is headquartered in Henrico County, VA.View Owens & Minor ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Markets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryMarket Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of Earnings Upcoming Earnings AstraZeneca (4/29/2025)Booking (4/29/2025)DoorDash (4/29/2025)Honeywell International (4/29/2025)Mondelez International (4/29/2025)PayPal (4/29/2025)Regeneron Pharmaceuticals (4/29/2025)Starbucks (4/29/2025)American Tower (4/29/2025)América Móvil (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 10 speakers on the call. Operator00:00:00Good day and thank you for standing by. Welcome to the Owens and Minor Second Quarter 2024 Earnings Conference Call. Please be advised that today's conference call is being recorded. I would now like to hand the conference over to your first speaker today, Jackie Marcus, Investor Relations. Jackie, you may begin. Speaker 100:00:22Thank you, operator. Hello, everyone, and welcome to the Owens and Minor Second Quarter 2024 Earnings Call. Our comments on the call will be focused on the financial results for the Q2 of 2024 as well as our outlook for 2024, both of which are included in today's press release. The press release, along with the supplemental slides, are posted on the Investor Relations section of our website. Please note that during this call, we will make forward looking statements. Speaker 100:00:52The matters addressed in these statements are subject to risks and uncertainties, which could cause actual results to differ materially from those projected or implied here today. Please refer to our SEC filings for a full description of these risks and uncertainties, including the Risk Factors section of our annual report on Form 10 ks and Quarterly Reports on Form 10 Q. In our discussion today, we will reference certain non GAAP financial measures and information about these measures and reconciliations to the most comparable GAAP financial measures are included in our press release. Today, I am joined by Ed Paseka, Owens and Minor's President and Chief Executive Officer and John Leon, the Interim Chief Financial Officer and Senior Vice President of Finance and Corporate Treasurer. I will now turn the call over to Ed. Speaker 200:01:45Thank you, Jackie. Good morning, everyone, and Speaker 300:01:47thank you for joining us on Speaker 200:01:48the call today. It's been an exciting past few weeks here at Owens and Minor. Last Tuesday, we shared with all of you our definitive agreement to acquire Rotech Healthcare Holdings Incorporated. The addition of Rotech aligns with our strategy to strengthen and expand our existing patient direct business as one of the premier suppliers to support home based care. Combining our organizations allows us to improve our capabilities, broaden our reach and ultimately improve our service levels to patients, providers and payers. Speaker 200:02:21And furthermore, it accelerates our pace to achieve our long term patient direct revenue target of $5,000,000,000 by 2028, demonstrating our commitment to sustainable growth and driving long term shareholder value. Turning to our Q2 performance, it was business as usual for Owens and Minor as we hit our internal expectations with another strong quarter and made progress against our long term strategic goals we outlined during our Investor Day in December of 2023. The underlying strength of our business is evident with top line growth in both of our business segments and improved profitability. We are excited about the second half of twenty twenty four as we expect to outperform the first half of this year, a continuation of historical trends with strong back half performances. While John Leon, our Interim Chief Financial Officer will do a more thorough review of our financials, I would like to briefly highlight a few of our operational and financial achievements from the Q2. Speaker 200:03:24Our Products and Healthcare Service segment generated $2,000,000,000 in revenue, reflecting a 4% improvement over this time last year. Our Medical Distribution division's strong Q2 was the result of exceptional same store sales growth, enhancement in our supplier funding programs and the onboarding of new business wins. Our Global Products division also experienced some growth at the top line and further improvements in profitability. At our Investor Day, we outlined our plan to optimize the P and HS segment through 1, leveraging the scale of the channel profitability 2, growing our Owens and Minor branded product portfolio and 3, expanding into adjacent channels and markets. In our first two quarters of 2024, we are already making progress in these areas with a particular focus on driving greater efficiencies that in the Q2 reduced our manufacturing, transportation and distribution costs. Speaker 200:04:25These efforts combined with inflation mitigating tactics gave us the financial flexibility to reinvest in our business while also doing exactly what we said we would do, increasing the overall profitability of this segment. Our Patient Direct segment posted $660,000,000 in revenue in the 2nd quarter, a 4% year over year improvement, driven by strong growth in diabetes and sleep supplies. Our growth is even more impressive given the particularly strong second quarter we had this time last year. During the quarter, we continue to focus on our key initiatives along with our alignment on the commercial organization within the Apria division to improve growth in respiratory, oxygen and the sleep journey. By the end of the quarter, we began to see that alignment deliver improved growth. Speaker 200:05:16As a reminder, we typically see stronger performance from this segment in the second half of the year and we expect a similar outcome in 2024. From a longer term macro perspective, our Patient Direct segment has considerable tailwinds supporting our organic growth efforts. From a demographic perspective, there are an estimated 133,000,000 Americans who suffer from at least one chronic condition, with 40% of American adults suffering from multiple chronic conditions and many more still not yet diagnosed, particularly in diabetes and sleep apnea. These demographic trends make us excited about our Patient Direct segment despite the groundswell of support for weight loss medications. Moreover, we are not currently seeing an impact from the use of GLP-1s on our served patient population. Speaker 200:06:08The diabetic patients we serve are primarily type 1 or insulin dependent, which requires continuous glucose monitoring regardless of GLP-one use. With respect to sleep apnea patients, while GLP-1s may help some patients, there are still 80% of the population with sleep apnea that are not yet diagnosed. As I noted earlier, we announced our intent to acquire ROTEC, which will be an expansion of our Patient Direct segment. Rotech brings a wealth of expertise in respiratory and home medical equipment, aligning perfectly to deliver exceptional care, innovative solutions and top notch service levels for patients, providers and payers. Being just a few months into our long term strategic plan, we are progressing as expected in both segments. Speaker 200:06:56Our team has done a tremendous job in just the 1st two quarters since launching our Vision 2028 plan at Investor Day. From driving efficiencies, improving customer service, to building strong organic growth channels and the plan to add Rotech to our Patient Direct segments, all of which proves we're on the right path and only just getting started. We remain dedicated to achieving the objectives set forth during our Investor Day in December 2023 and our performance thus far reflects that commitment. I would now like to turn the call over to our Interim Chief Financial Officer, John Leon to discuss our Q2 financial performance in more detail. John? Speaker 400:07:39Thanks, Ned, and good morning, everyone. I will be providing an overview of our financial results and some key factors that drove our performance in the 2nd quarter, as well as our outlook for the remainder of the year. Our revenue for the quarter was $2,700,000,000 up 4% compared to the prior year with solid growth in both segments. Products and Healthcare Services grew 4% overall as compared to the prior year with 5% year over year growth in our medical distribution division as same store sales and net new customer wins drove the top line change. Patient Direct revenue of $660,000,000 was up 4% compared to the Q2 of last year. Speaker 400:08:21Major therapy categories like diabetes, sleep supplies and wound again had strong performance, although certain respiratory therapies such as NIV and oxygen were below expectations. Within Patient Direct, patient eligibility verification continued to regain momentum. However, a meaningful yet decreasing backlog of customers extended into the Q2. We should be clear of these onboarding timing issues as we move through the second half of the year. Gross profit in the second quarter was $544,000,000 or 20.4 percent of net revenue, reflecting margin expansion of 11 basis points as compared to the Q2 of last year. Speaker 400:09:02This improvement is largely the benefit of investments in efficiency and productivity over the last several months. Our distribution, selling and administrative expenses for the quarter were 469,000,000 dollars up from $455,000,000 in the Q2 of 2023. The increase is primarily due to sales growth as DS and A was just below 18% of revenue for both this year and last year. GAAP operating income for the quarter was 20,300,000 dollars up 87% year over year and adjusted operating income was $76,300,000 Adjusted operating income was up 23% year over year. Interest expense for the Q2 was $36,000,000 down 12% compared to $41,000,000 in the Q2 of 2023. Speaker 400:09:50This is largely due to the nearly one full term reduction in leverage in the last 12 months, partially offset by the impact of higher interest rates versus last year. In the Q2, we recorded a one time tax charge of $17,000,000 or $0.22 per share related to a recent decision associated with notices of proposed adjustments that we received back in 2020 2021. This was just communicated to us in late June of 2024. Due to the nature of this charge, this item is included in our GAAP to non GAAP reconciliations. The matter at hand, as we've discussed in previously filed SEC documents, is related to past transfer pricing methodology, which is no longer employed. Speaker 400:10:33There is an expected related cash payment to be made in the second half of the year in a range of $30,000,000 to $35,000,000 We believe the matter will be concluded without further impact to our financial results. Our GAAP effective tax rate reflects this charge and was negative 89.9 percent for the quarter. The adjusted effective tax rate was 28.9%. Our GAAP net loss for the quarter was $31,900,000 or a loss of $0.42 per share compared to the Q2 of last year when the net loss was 28,200,000 dollars or $0.37 per share. Adjusted net income for the quarter doubled to $28,200,000 or $0.36 per share from $14,200,000 or $0.18 per share during the Q2 of 2023. Speaker 400:11:18Adjusted EBITDA was $127,000,000 up 12% versus $113,000,000 reported in the Q2 of last year. Also we generated $116,000,000 of operating cash flow this quarter, a strong improvement versus Q1 of 2024. This will allow us to reduce net debt by $70,000,000 We anticipate a good cash flow generation year that will include typical lumpiness quarter to quarter and we remain intensely focused on cash flow generation. With respect to our current outstanding debt, we have $171,000,000 of a series of notes which is due in December of this year. Earlier this week, we gave notice to redeem those notes at par in September and we'll do so with cash on hand. Speaker 400:12:01We remain committed to delivering our 2024 guidance. We expect revenue to be in the range of $10,500,000,000 to $10,900,000,000 adjusted EBITDA to be in the range of $550,000,000 to $590,000,000 and adjusted EPS with a midpoint of $1.55 per share and overall range of $1.40 to 1 0.70 Now as in prior years, we expect to see modest sequential growth between the 2nd and the 3rd quarters and greater sequential growth from the 3rd to the 4th quarter. And again, I want to remind you that this guidance excludes any impact of the Rotech acquisition. With that, I'll turn the call over to the operator for the Q and A session. Operator? Operator00:12:42Thank you. We will now begin the question and answer session. Your first question comes from the line of Michael Cherny with Leerink Partners. Please go ahead. Speaker 500:13:03Good morning and thanks for taking the question. Operator00:13:11My apologies. Can you press star 1 again please? Speaker 200:13:16Sorry, Michael, we lost you. Speaker 400:13:23Operator, why don't we move on to the next question and Mike will get back in line. Yes. Operator00:13:27Michael, your line is now open. Speaker 500:13:30Hi. Can you hear me this time? Speaker 200:13:32We can, Michael. Speaker 500:13:34Okay. That was a first. We'll see if that happens again. Speaker 400:13:37Sorry about that. I don't know what happened. Speaker 500:13:41Yes. Called a Friday. That's right. Speaker 400:13:44I want to talk about some Speaker 500:13:45of the operational plans that you've had put in place, in particular the progress you made on the products and healthcare services side. As you think about the moving pieces on margins, you were kind of flat sequentially. Where are the biggest opportunities to expand in the back half of the year? Is it volume? Is it that unlocking of the backlog of customers? Speaker 500:14:06And how does the dynamics around the tariffs that are expected to go into place impact and not impact you relative to the sourcing side? Speaker 200:14:16Let me take those probably somewhat in reverse orders. From on the tariff aspect, it's going to have a minimal impact on us since significant portion of our products are manufactured in our own facilities, whether that's in the U. S. Or whether that's in Mexico, Honduras, so in the Americas. Our glove footprint is not in China. Speaker 200:14:35We have, as we've talked in the past about more than half of our gloves we're making in our own factories and those factories are in Southeast Asia, not in China. So it's going to have minimal impact really on our proprietary, our private label products. If I think about the levers we have in the back half of the year within our product and healthcare services, it's the continued execution on sourcing. As we've seen prices come down in overall, let's just take it main category of PPE, we've done a really good job continuing to source raw materials at lower rates to make sure that as those prices come down, our costs are coming down correspondingly with them. The other aspect of it is really in operational effectiveness in our P and HS segment. Speaker 200:15:23Continue to look at our footprint, continue to look at the right level of new advanced automation and technology in the warehouses to drive operating efficiencies. So we saw some of the improvement in this quarter in DS and A or distribution selling and administrative expenses. There's where the opportunities continue to lie. Longer term, if you go back to our strategy, really the longer term impact is the expansion of our private label or proprietary product portfolio that takes time as we build the product portfolio out and then continue to work with our customers to show the value of it. And then even further along the line is adjacency. Speaker 200:16:02So hopefully that helps talk about really how we're thinking about the impact of the tariffs, how we're thinking about using our continuous improvement and operating model to continue to drive operating efficiencies out and then some of the longer term and midterm opportunities. Speaker 400:16:21Thanks, Ed. If I can just ask a Speaker 500:16:22second one on cash flow. Speaker 400:16:26I know that was Speaker 500:16:26a big focal point earlier in Speaker 400:16:28the year when you gave guidance, you talked about some of Speaker 500:16:30the customer onboarding. Can you talk about the dynamics behind the reversal this quarter and how that should factor in, in terms of your cash generation versus use, over the course of the year, especially as you think through normalizing the onboarding of some of those large customer wins you had? Speaker 400:16:46Yes, Mike, it's John. So obviously, as you mentioned, we talked before about the need to add inventory for those onboarding activity and that could also slow down AR a little bit when you bring on large customers like we did in distribution. What you saw in Q2 was a little more lift in inventory, but that was offset by payables and payables kind of offset that pretty nicely. Like Q1, we also had the quarter end on a Friday, which is actually beneficial to our payables. And we have been pretty successful in driving out payment terms where appropriate with parties. Speaker 400:17:18So that combination is going to continue to help us out in the back half of the year. But people might also get the seasonality in the back half of the year, particularly in Patient Direct, which will have very well, it's very attractive cash flow as the year goes on. And their contractual allowances should drop as the year goes on as well. So I think we'll see more efficiency. Consequently, we'll see more efficiency in working capital around payables, we see those in inventory. Speaker 400:17:44And if you look at the seasonal list now, keeping in mind that what you're looking at is a point in time at the last day of the quarter. So we're actually more efficient in Q2 than we saw. For example, average inventory was lower than it was at the very end of the quarter. So we were able to get that cash flow and reduce debt. But I think as the year goes on, that working capital efficiency and then the seasonality business will drive pretty attractive cash flow compared to the first half of the year. Speaker 500:18:11So will you have meaningful cash flow conversion over the course of the year? I know that was a point of contention earlier in the year. Speaker 400:18:17We will do. I would be very disappointed if we didn't do quite a bit better in the second half than we've done in the first half. Got it. Thanks so much. Operator00:18:28Your next question comes from the line of Kevin Caliendo with UBS. Please go ahead. Speaker 600:18:35Good morning, guys. Thanks for taking my question. Speaker 300:18:40First, can we talk a Speaker 600:18:41little bit, there's been a lot of interest around what's going on with shipping costs and how it impacts the channel. The tariffs are one thing, but the shipping costs have the ones that we can track anyways have risen dramatically. And I guess I'm trying to understand how it impacts you, how it impacts the industry. Does it help you that you're sure and does it make your products that are manufactured domestically more attractive? Just trying to understand the impact across channel. Speaker 200:19:13Yes. So it's primarily an impact on the PNHS segment, not necessarily in the Patient Direct segment. Yes, for those products that we're manufacturing nearshore, it has to create some level of an advantage for us. But again, I talked earlier that about half of our gloves were making our own factory in Southeast Asia and bringing them over. It's impacted us in a couple of different ways. Speaker 200:19:37As we started to see those rates start to rise, we have made some investment in incremental inventory coming over in advance of some of those larger increases that we're seeing in the marketplace. But ultimately, this is going to have a bigger impact on those that do primarily all of their sourcing or the vast majority of their sourcing from overseas. Look, it's a headwind that we know we have in the business. It's also part of how do we utilize our operating model to continue to try to offset that, whether it's advanced shipments prior to some of those increases, but also continue to look at different ways to more efficiently bring the product over. But it is going to create some level of a headwind in the business in the back half of the year. Speaker 600:20:23So what you're saying is you're trying to get product in sooner, maybe you're going to build up more inventory before it starts to affect as much as you possibly can and hope that customers will be willing to buy those sooner because they know the prices are likely to go higher. Does that in general? Speaker 200:20:43And it may not even necessarily them buy the product sooner. It's just to have a better landed cost on the product than Speaker 400:20:51not. Good. Speaker 600:20:54Maybe this is one for Jonathan. The patient direct ramp in the second half is there it's a little bit more than normal seasonality, it looks like to me. Can you just give us a little bit of comfort or rationale behind why that there will be this acceleration? I know there were investments, but if you can maybe go a little deeper on that, that would be great. Speaker 400:21:19Yes, Kevin. The biggest factor, as I indicated in my remarks, was that we're still dealing with the backlog in Patient Direct that frankly is a holdover from change that we probably underestimated because the extent of that impact in Q1 to Q2. We have a normal queue of people waiting for supplies all the time, but this is substantially larger than it would normally be. And those are primarily sleep patients. So it's a little more process associated with them. Speaker 400:21:47So if you factor that, we are catching up. There's a lot of manual effort going to that catch up, but we are catching up and we're clearing that backlog. So you take that combination then with the normal seasonality in the business, we're pretty confident in a much stronger second half. Speaker 200:22:03And I'll just add 2 other things as one is we clearly understood that when we added additional commercial resources, they would create some level of I'm going to call it disruption, but some level of impact in the beginning of the year here with the expectation that it takes about 12 months for them to provide a positive impact. So we'll see that as that progresses in the year. The other thing, if you look at Q2 year over year, last year Q2 growth rate was pretty strong. So those are some other factors that give us the comfort in the back half of the year and the growth. Speaker 400:22:35Great. Thank you, guys. Thanks, Kevin. Operator00:22:38Your next question comes from the line of John Stansl with JPMorgan. Please go ahead. Speaker 300:22:44Great. Thanks for taking the question. Just following up on the plan around Patient Direct. Is there just a way to frame, given you have some visibility into this backlog about how you think about the impact on patient direct top line growth? And then now that we're kind of a month into the Q3, is this something that you think now is this change is kind of coming in the rear view that will be more of a 3Q benefit? Speaker 300:23:08Or is this something that kind of could progress into 4Q? Speaker 400:23:13Yes, John. It's John William. It wouldn't help me think about it. So what happens, the eligibility verification process had become very manual very quickly. And we're doing a very good job of clearing that and getting better at that and bringing on new providers to help us with that process. Speaker 400:23:30A way to think about it, and I would call it back over at any point in time, there's a queue of 10,000 customers waiting for supplies and that we saw that into June growth was much as 50,000. So that is getting better now that we're getting to the 3rd quarter will continue to get better throughout the year. But that has certainly impacted the growth. And as I said earlier, a lot of it is predominantly sleep supplies and that's very attractive margin business that we're waiting to get online. Speaker 300:23:58Great. And then just kind of thinking about gross margins that have stepped down sequentially from the Q1. Now I normally think of this as kind of gross margin stepping up throughout the year. Is that kind of slight step down that you saw, is that more kind of attributable to the patient direct, I guess, mix shift? Or is there other factors you highlight about kind of what drove that? Speaker 300:24:22And then I would assume, giving reaffirmed guidance, we should just see a bit of a steeper ramp into the back half for gross margins. Is that kind of the right way to think about it? Speaker 400:24:30That is the right way to think about it. Yes, mix shift in patient direct can be meaningful, and we've thought that before that sleep and respiratory areas have higher margin, things like diabetes, which has been growing very nicely for us. Speaker 300:24:43Great. Thank you. Operator00:24:46Your next question comes from the line of Stephanie Davis with Barclays. Please go ahead. Speaker 700:24:52Hey guys, thank you for taking my questions. Now that you've had a little bit of time to just have the market digest the Rotech acquisition announcement, I was hoping you could tell us about some initial feedback from your payer and provider customers and how they're thinking about the deal? Speaker 200:25:08Yes. I'll just talk a little maybe I'll start it at a high level. I think it's been clear the feedback has been that this is clearly in line with the strategy you talked about, about continuing to invest inorganically, specifically in the Patient Direct space, continuing to provide a better solution. It's still early on. So to get the patient and the payer feedback, that's still in process. Speaker 200:25:34But overall, it's been extremely positive. I think overall from a standpoint, we believe that this is going to ultimately provide a much better experience for the patient, the ability to focus on a single company to support them as well as be able to get their products hopefully potentially more efficiently. And then the same with the payers being able to have continue to work with us. So it's early on. I think we'll continue to gather that information, but that's where we are on it right now. Speaker 700:26:07And a follow-up on Patient Direct, you did call out some weakness in the quarter on NIV and oxygen. Could you call out any trends or if that's more of a one off with the owned business just given the exposure at Rotex? Speaker 400:26:25No, I would tell you what we've seen from now a couple of quarters now, Stephanie, we've talked about when we're not doing what we should be doing, expect to do in terms of growing, NIV and oxygen. I would call that unique to us. I'm confident saying that's unique to us and we have plans in place and working on that to remedy that in the back half of the year. Speaker 700:26:45Okay. Maybe some learnings from the new deal. Thank you much. Speaker 400:26:48Exactly. Exactly. Operator00:26:51Your next question comes from the line of Daniel Groeslait with Citi. Please go ahead. Speaker 800:26:58Hi, thanks for taking the question. Let me go back to some comments you made around cash flow and that being meaningfully you expect that to be meaningfully better in the second half versus the first half. That would put you in kind of solidly positive free cash flow territory for this year versus your commentary last quarter where you thought you would be effectively flat or no free cash flow this year. So I'm just curious what changed in your thinking? Where are you outperforming your initial in the back half of this year? Speaker 800:27:39What's in the Speaker 200:27:40back half of this year? Speaker 400:27:43Well, yes, it does. First of all, Dave, it's John. Secondly, I would tell you the increased confidence in cash flow comes around our focus and the visibility into the working capital activities currently underway. We've talked about last couple of quarters about the inventory ramp and talked earlier about inventory being a little bit higher now for some shipping purposes getting ahead of that curve. But even throughout most of the second quarter, we saw inventory be pretty well moderating compared to Q1, We're in full a bit late in the quarter, but I think as we think about that and we get a little smarter about our AP and our AR and getting better terms from folks, I think we're pretty confident that cash will get better as the year goes on. Speaker 400:28:29We're seeing better collections on a regular basis that had a patient direct to the field. Speaker 800:28:35Got it. Okay. Okay. And there were some legal expenses this quarter, I think related to the Apria. Just curious what's driving that and if you expect to see increased legal expenses for the remainder Speaker 200:28:52of the year this quarter? Speaker 400:28:53No, nothing going forward. That was a one time settlement, an action that began before we bought Apria. So that has now been failed and behind us. So there'll be nothing else going forward associated with that. Okay, great. Speaker 400:29:06Thank you. Operator00:29:10Your next question comes from the line of Eric Coldwell with Baird. Please go ahead. Speaker 900:29:17Thank you very much. I apologize if I missed a couple of these. For some reason I've had a hard time with the connection here, just a little bit hard to understand some things. In 2Q, did you break out the difference between medical distribution growth and products growth that combined to got you to the 4%? Did you give the growth rate? Speaker 900:29:42No, Speaker 200:29:43we did not. Speaker 900:29:45Can you? Speaker 400:29:49Well, I think we said net distribution grew 5% and overall segment grew 4%. So, I think Okay. Speaker 900:29:55I didn't hear that. It's been a bad connection today. Yes. Okay. And then on the cash flow, I know you've given a number of reasons why it improves, but I still am not sure why the original guidance was flat and now it's so much different. Speaker 900:30:16What was it that you're just fundamentally managing the business differently or things you expected through Q1 up to the last call just they're turning out differently than you originally expected. It just seems like a very different conversation 90 days later than it was 90 days ago. Speaker 200:30:38I think that's fair, Eric. And I think it comes down to as one is focus As we continue to look forward, I think you've got better visibility now into forecasting of where we think it where the opportunities in the lever are. And then it's execution on some of the initiatives we have to drive working capital improvement. So that's those three major factors are where it is. It's the focus, it's improved forecasting and our ability to execute on some of those opportunities. Speaker 900:31:11Great. And I'll just going to go back to the medical distribution growth of the 5%. Would you be capable of breaking out how much of that growth was market versus new wins? Yes. Or was it same store versus new wins? Speaker 200:31:28Yes. I think it's if I think about the 2 of them, they're relatively consistent. I mean so what's hard to do is our same store sales, if we look at our same store sales, they're consistent with that 4% and then our wins are consistent to help move that up further. And then there's still some remnants of some other losses we've had in the past that are rolling out. So that's the way I would think about it is from that standpoint. Speaker 900:31:55Got it. Okay. Thank you very much. I appreciate it. Operator00:32:00That concludes our question and answer session. I will now turn the conference over to Ed Paseka for closing comments. Speaker 200:32:07So thanks everyone and excited and thankful that everyone joined the call today. If we think about the future at Owens and Minor, we're extremely excited of what's yet to come in here. We continue to execute on our long term strategy. We continue to focus on our operating model. We continue to get excited about the potential and future integration and approval with the Rotech, rolling that into our patient direct business, which will provide, we believe, significant better service for our patients, providers as well as the payers and really pleased with the progress we've made to this point in time in our product and healthcare services business. Speaker 200:32:44So with that, appreciate the time today and look forward to talking again next quarter. Thank you. Operator00:32:49This concludes today's conference call. Thank you for your participation and you may now disconnect.Read morePowered by